HAE Stock Recent News

Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over time In first-of-its-kind prospective analysis, patients switching from prior prophylactic treatment to donidalorsen experienced further reductions in mean monthly HAE attack rates from baseline Donidalorsen demonstrated a favorable safety and tolerability profile across all cohorts Data to be presented today at EAACI Congress 2024 Ionis to host webcast on Friday, May 31 at 8:00am ET CARLSBAD, Calif. , May 31, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE) demonstrating significant and sustained reduction in mean monthly HAE attack rates and continued attack rate improvement of >90% with one year of

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.

MNSO, LSPD and HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 28, 2023.

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?

The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BOSTON , May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amount of notes.

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).